CV Risk After Hodgkin Lymphoma Lasts For Years
Those who survived Hodgkin lymphoma (HL) could have an increased risk for cardiovascular risk later in life, according to a recent study.
While HL survivors have a heightened risk of manifesting cardiovascular disease, it is unclear what the risk factors are for different cardiovascular disease and how long the increased risk lasts for.
_______________________________________________________________________________________________________________________________________________________________
RELATED CONTENT
New Therapy Keeps Hodgkin Lymphoma From Progressing
Primary Hodgkin Lymphoma Masquerading as a Klatskin Tumor
_______________________________________________________________________________________________________________________________________________________________
“This retrospective cohort study included 2524 Dutch patients diagnosed as having HL at younger than 51 years (median age, 27.3 years) who had been treated from January 1, 1965, through December 31, 1995, and had survived for 5 years since their diagnosis,” said the study’s authors.
After data was collected from medical records and primary care doctors, researchers graded cardiovascular events, including valvular heart disease (VHD), coronary heart disease (CHD), and cardiomyopathy and congestive heart failure (HF), based on the Common Terminology Criteria for Adverse Events, version 4.0.
The researchers found 1713 cardiovascular events in 797 patients after a median follow-up of 20 years. Participants still had a 4- to 6-fold heightened CHD or HF incidence ratio compared to those in the general population after 35 years. This corresponded to 857 excess events per 10000 person-years.
While researchers observed elevated CV risks in all age groups, those treated for Hodgkin’s prior to age 25 were at the greatest risk.
The complete study is published in the April issue of JAMA Internal Medicine.
-Michelle Canales Butcher
Reference:
van Nimwegen FA, Schaapveld M, Janus CPM, et al. Cardiovascular disease after Hodgkin lymphoma treatment. JAMA Intern Med. 2015 April [epub ahead of print] doi: 10.1001/jamainternmed.2015.1180.